The fruit fly cancer researcher who built his first prototype out of lollipop sticks and straws

Caíque Costa, a biomedical scientist, founded FlyFast in 2024 to commercialize cancer genetics research using fruit flies as a primary model organism. The company filed a non-provisional patent in 2026, marking a critical regulatory milestone for the early-stage venture. Costa's work centers on leveraging the genetic similarities between fruit flies and humans to accelerate cancer research and drug discovery pipelines—a biological approach that has shown efficacy since Thomas Hunt Morgan's foundational 1910 experiments established Drosophila melanogaster as a standard research model.

The scientific rationale underpinning FlyFast's platform is compelling from a research efficiency standpoint. Fruit flies and humans share approximately 60% of genes broadly, but the overlap rises to approximately 85% when examining disease-associated genes specifically. This genetic proximity, combined with the organism's short reproduction cycle and low maintenance costs, positions fruit flies as an attractive alternative to more expensive mammalian models for initial screening and validation phases in cancer research. According to Costa, "Flies are a very fast model for retaining results and making breakthrough discoveries," and they remain "cheap to maintain and relatively simple to work with."

Costa's background reflects both rigorous formal training and an entrepreneurial mindset. He completed his undergraduate degree at Brazil's Bahiana School of Medicine and Public Health before earning a Ph.D. from Tulane University in 2025. Notably, his initial prototype for FlyFast's platform was constructed from lollipop sticks and straws—a telling detail that underscores how early-stage biotech ventures often emerge from resource-constrained environments where ingenuity substitutes for capital. This bootstrap approach is particularly relevant given that the global laboratory equipment sector alone represents approximately $45 billion in addressable market value, with significant opportunity to address friction points in physical scientific workflows.

The venture exists at the intersection of traditional biomedical research and emerging efficiency imperatives. While artificial intelligence and computational tools have captured significant investor attention in scientific research—as evidenced by ventures such as Demis Hassabis's Isomorphic Labs—substantial friction remains in the physical, hands-on components of laboratory science. FlyFast's model-organism platform targets this gap by reducing time-to-results and capital requirements for early-stage cancer genetics validation, potentially enabling faster hypothesis testing and resource allocation in downstream development.